CTN :41204584
18 Aug, 2025
NA
Tender For procurement of drugs/medicines/iv fluids - drugs, tab. chlorzoxazone+ paracetamol+ diclofenac 250mg+325mg+50mg, inj. propofol mct-lct 2% w/v 20mg/ml, plastic p.d. fluid (capd bags) 1.5% 2 ltr, plastic p.d. fluid (capd bags) 2.5% 2 ltr, inj. nivolumab 40mg, inj. nivolumab 100mg, inj. purified vi conjugate ploysaccharide typhoid vaccine 25mcg, tab. loralatinib 100mg, tab. enalapril 2.5mg, inj. mepolizumab 100mg, cream/oint betamethasone + clioquinol 0.1%+ 3% (30gm), inj. golimumab 50mg 0.5ml, tab. ivabradine 5mg, inj. pembrolizumab 100mg, tablet endoxifen 8 mg, oint. mometasone 0.1% (15gm), inj. mitoxantrone 20 mg, inj. pancuronium bromide 4mg 2ml, inj. insulin degludec disposable pen with penfill 100 iu, insulin degludec + insulin aspart pen with penfill 2.56mg/1ml+ 1.05mg/1ml, tab. ribociclib 200mg, tab. flavonoids containing micronize extract of rutaceae eq to diosmin 450mg +50 hesperidine 500 mg, inj. somatrogon 24mg pfp, syp. combination of aluminium hydoxide magneshium hydro-xide/trisilicate simethicone, class="text-red-selected">activated methyl polysilox et
c. 150ml-200ml,
inj.
cefoperazone 1gm, tab deflaza
cort 24mg, oint.
clobetasol 0.05%w/w (30gm), tab. deflaza
cort 30mg, tab a
ceno
coumarol 1mg,
inj. 6%isotoni
c balan
ced hydroxy ethyl star
ch based
colloid solution. ele
ctrolyte
composition similar to plasma. na+ 135to 140 mmol/l
cl- 110 to120mmol/lk+ 3.5 to 4.5 mmol/l
containing adequate a
cetate, malate osmolality 285 to 300 mosm/l,
inj. rapid a
cting insulin vial,
inj. avelumab 200mg/10ml,
inje
ction risperidone
inje
ction (long a
cting) 25 mg,
inje
ction risperidone
inje
ction (long a
cting) 37.5 mg,
inje
ction gly
ceryl trinitrate 5 mg/ml, tablet artemether 40 mg + lumefantrine 240 mg,
capsule aprepitant 80 mg, tab. gilteritinib 40mg, tablet quinine 300 mg, tablet tenofovir disproxil fumarate 300 mg + lamivudine 300 mg + efavirenz 600 mg, tablet tenofovir disproxil fumarate 300 mg + lamivudine 300 mg + dolutegravir 50 mg, e/d ofloxa
cin + dexamethason 0.3 % + 0.1 %, topi
cal lido
caine 2% to 4% (hydro
chloride),
inje
ction
cetuximab 500mg,
inje
ction daratumumab 100mg,
inje
ction daratumumab 400mg,
inje
ction ligno
caine h
cl (topi
cal) 42.7mg/ml 4% (30 ml),
inje
ction thiopentone 500mg, tablet dabrafenib mesylate 75mg, fluid i
codextrin 7.5% 2lt,
inj. follitropin alfa and lutropin alfa(900iu rhfsh + 450rhlh) 1.44 solution pfp, suppository para
cetamol 80mg, suppository para
cetamol suppository 170 mg,
inje
ction se
cukinumab 150mg,
inje
ction sodium diatrizoate & meglumine diatrizoate 76% - pa
ck of 50ml,
inje
ction metoprolol 5 mg 5ml, tablet s-atenolol 25mg, tablet
carbamazepine
controlled release 200mg, eye drop
combination of bori
c a
cid, naphazoline et
c 1.1% w/v+ 0.01% w/v (5 ml), ointment framy
cetin 1% (20gm), syrup metronidazole 200mg, tablet metronidazole 200 mg, tablet sodium pi
cosulfate 10 mg, tablet magnesium hydroxide, aluminum hydroxide, simethi
cone 185mg+830mg+50mg, syrup prednisolone 5mg/5ml (60ml), tab.
cal
citriol 0.25 m
cg,
inje
ction insulin aspart biosyntheti
c & meta
cresol penfill with pen 300 iu (3ml),
inje
ction insulin aspart premix analogue 30/70 pen 3 ml,
inj. human albumin low sodium/ salt
contains less than 80mmol/l 100ml 20% 100ml,
inj. human albumin low sodium/ salt
contains less than 80mmol/l 50ml 20% 50ml